Is the price fair?
What PBH's price assumes
Prestige Consumer Healthcare Inc. trades at 13.3× earnings against 24.4× for the median Drug Manufacturers - Specialty & Generic name, cheaper than its own group.
13.3
Trailing P/E · Drug Manufacturers - Specialty & Generic median 24.4 · cheaper than the typical name in its group
- Price / sales
- 2.69
Price / sales · as of 2025-Q4
- Free cash flow yield
- 11%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.5%
- Growth the price implies
- −5.0%
Growth the price implies · The price pays for −5.0% free cash flow growth a year for a decade; the business has delivered +3.5% a year over the last three.
Details›
- Price / book2025-Q4
- 1.62
- EV / EBIT2025-Q4
- 12.2
- EV / sales2025-Q4
- 3.57
- Healthcare median P/E362 names
- 31.5
- Drug Manufacturers - Specialty & Generic median P/E32 names
- 24.4
- Free cash flow, trailing twelve months
- $246M
- Market capitalisation
- $2.23B
- 3-year revenue growth
- −1.2%
- 3-year free cash flow growth
- +3.5%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $51.35 |
| Its own P/E history, median | $59.12 |
| Its own P/E history, upper quartile | $70.91 |
| 52-week range | $45.44 – $70.21 |
| Today | $52.18 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - Specialty & Generic
Ranks #9 of 28 by Smart Score